Therapeutic Solutions International, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy George Dixon
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 701 Wild Rose Lane Elk City ID United States of America 83525
- IPO Date
- Jun 24, 2008
- CIK
- 0001419051
- Website
- therapeuticsolutionsint.com
- Similar Companies
- Business
- Therapeutic Solutions International, Inc. is a biotechnology company specializing in the development and commercialization of immune-modulatory agents and therapeutics for a range of diseases including cancers, schizophrenia, suicidal ideation, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), lung pathology, and Parkinson's disease. Its product portfolio includes patented and proprietary formulations such as QuadraMune, a synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone designed to enhance natural killer cell activity and cytokine production; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical spray form of pterostilbene; IsoStilbene, an injectable formulation; NeuroStilbene, an intranasal form; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and the NLRP3 Trifecta, a combination product that includes NanoPSA and green tea extract (GTE-50). The company is also engaged in developing dendritic cell vaccines through its StemVacs platform targeting cancers and Parkinson's disease. Therapeutic Solutions produces nutraceuticals such as ProJuvenol, an anti-aging capsule product, alongside these therapeutic offerings. Founded in 2007, the company is headquartered in Elk City, Idaho, and operates primarily within the United States. Recently, Therapeutic Solutions International has undergone significant operational changes, including its voluntary delisting from public markets in 2025 to focus on advancing its subsidiaries, including Breathe Biologics, Campbell Neurosciences, and Res Nova Bio, which are seen as key to its future technology development and potential monetization through sales or partnerships. The company formed ALS Biologics Inc., a subsidiary dedicated to accelerating the development of its assets related to amyotrophic lateral sclerosis treatments. Therapeutic Solutions secured exclusive licensing rights for a patented adult stem cell technology aimed at treating chronic traumatic encephalopathy and traumatic brain injury, enhancing its central nervous system therapeutic pipeline. The company also announced plans to start a breast cancer clinical trial using its FloraStilbene product, reinforcing its commitment to expanding clinical applications of its therapeutics. Therapeutic Solutions International operates in the biotechnology and healthcare sectors focusing on immune modulation, cancer immunotherapies, and neurological disorder therapeutics. It targets patients with serious chronic and acute conditions through a combination of pharmaceuticals, biologics, and nutraceutical products. The company leverages its proprietary technology platforms, including StemVacs, to develop novel therapeutic vaccines and immune-enhancing agents. Its business strategy involves both direct therapeutic product development and strategic subsidiary investment to enhance innovation and value capture in niche biomedical markets.
Therapeutic Solutions International to Voluntarily Delist
Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation
Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities
Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™
Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease
Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression
Therapeutic Solutions International Collaborates on Peer-Reviewed Publication on Personalized Immunotherapy for Brain Cancer Using mRNA
Therapeutic Solutions International Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils
Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Clinician and San Diego Top Doctor to Scientific Advisory Board
Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It
Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia
Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial
Therapeutic Solutions International Prevention Subsidiary Campbell Neurosciences Receives Notice of Allowance on Suicide Prevention Drug Candidate
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™
Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022